Clinical Trials
5 trialsNCT07112053 2026-04-06
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT06572800 2025-10-08
Tka Assay for CDK4/6i
Yale University
Phase NA Completed
NCT06026657 2025-07-08
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT04190056 2023-08-31
Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer
University of California, San Francisco
Phase 2 Terminated
NCT00338728 2020-01-27
Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed